ENTR-601-45

Phase 2Small molecule

ENTR-601-45 is one of 5 small molecule programs targeting Duchenne Muscular Dystrophy (DMD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Duchenne Muscular Dystrophy (DMD)Not yet recruiting

Duchenne Muscular Dystrophy (DMD)Phase 2

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Duchenne Muscular Dystrophy (DMD)

#DrugCompanyPhaseTrials

SGLT2 Inhibitor

Eli Lilly

Phase 1

1 2

Bmn 351

BioMarin Pharmaceutical

Phase 2

1 3

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Phase 1

1 4

ENTR-601-45

EEntrada Therapeutics, Inc.

Phase 2

2 5

ENTR-601-44

EEntrada Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

Duchenne Muscular Dystrophy (DMD)

NCT07038824

Q1 2032

Phase 2Not yet recruiting

Duchenne Muscular Dystrophy (DMD)

NCT07682129

Clinical

Trials by Indication[1]

Duchenne Muscular Dystrophy (DMD)2 trials

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping With an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45)

Recruiting·EEntrada Therapeutics, Inc.·Preclinical·NCT07038824·24 enrolled

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Not yet recruiting·EEntrada Therapeutics, Inc.·Phase 2·NCT07682129·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ENTR-601-45. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ENTR-601-45 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ENTR-601-45. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Entrada Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEntrada Therapeutics, Inc.

ENTR-601-45

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q1 2032

Trials by Indication[1]

Duchenne Muscular Dystrophy (DMD)2 trials

References

Drug Info

Quick Facts

Related News